PTD-mediated delivery of α-globin chain into Κ-562 erythroleukemia cells and α-thalassemic (HBH) patients’ RBCs ex vivo in the frame of Protein Replacement Therapy

BACKGROUND: α-Thalassemia, a congenital hemoglobinopathy, is characterized by deficiency and/or reduced levels of α-globin chains in serious forms of α-thalassemia (HbH disease/Hb Bart’s). This research work deals with a Protein Replacement Therapy approach in order to manage α-thalassemia manifesta...

Descripción completa

Detalles Bibliográficos
Autores principales: Miliotou, Androulla N., Papagiannopoulou, Dionysia, Vlachaki, Efthymia, Samiotaki, Martina, Laspa, Dimitra, Theodoridou, Stamatia, Tsiftsoglou, Asterios S., Papadopoulou, Lefkothea C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290593/
https://www.ncbi.nlm.nih.gov/pubmed/34284828
http://dx.doi.org/10.1186/s40709-021-00148-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290593/
https://www.ncbi.nlm.nih.gov/pubmed/34284828
http://dx.doi.org/10.1186/s40709-021-00148-3

Ejemplares similares